Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
61 - 70 of 74
- ChemPro Tools - Development of chemical tools and proteomics methodology for the study fo proteolytic systems.From1 Jan 2012 → 31 Dec 2015Funding: SBO (Strategic basic research)
- Cysteine protease inhibitors for protozoan infections: metacaspases as promising new targets.From1 Oct 2011 → 31 Aug 2013Funding: FWO fellowships
- Topically applicable long-lasting glucocorticoid receptor agonists for the treatment of inflammatory skin diseases.From15 Apr 2011 → 14 Apr 2012Funding: Industrial enterprises, IOF - Industrial Research Fund
- Secondary organic aerosol formation from monoterpenes: gaps in our current understanding.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Specific blocking of autophagy processess via inhibition of Atg4B? An approach based on drug-like inhibitors and activity-based probes.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Active center assisted selection and assembly: a bottom-up approach to druglike protease inhibitors using urokinase plasminogen activator as a model target.From1 Jan 2011 → 31 Dec 2011Funding: BOF - Other initiatives
- A fragment-based approach to protease inhibitor development.From1 Oct 2010 → 30 Sep 2020Funding: BOF - ZAP BOF mandates, BOF - Research professorship
- Development of urokinase-type plasminogen activator (uPA) inhibitors as potential drugs in anti-metastatic cancer therapy.From1 Oct 2010 → 30 Sep 2012Funding: FWO fellowships
- Fibroblast Activation Protein (FAP) and cancer: development of inhibitors for the treatment of malignant disease and their use as biomarkers FAP probes.From1 Oct 2010 → 30 Sep 2014Funding: IWT personal funding - strategic basic research grants
- From protease inhibitors with increased target residence time to activity-based probes: useful tools in different areas of drug discovery.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 129
- UPLC-TQD-MS/MS method validation for quality control of alkaloid content in lepidium meyenii (Maca)-containing food and dietary supplements(2024)
Authors: Ngoc Thao Hien Le, Kenn Foubert, Mart Theunis, Tania Naessens, Murat Bozdag, Pieter Van Der Veken, Luc Pieters, Emmy Tuenter
Pages: 1 - 11 - Design and synthesis of selective DPP9 inhibitors(2024)
Authors: Siham Benramdane, Pieter Van Der Veken, Hans De Winter
Number of pages: 232 - Next generation fibroblast activation protein (FAP) targeting PET tracers(2023)
Authors: Christian B.M. Poulie, Vladimir Shalgunov, Filipe Elvas, Yentl Van Rymenant, Euy-Sung Moon, Umberto Maria Battisti, Joni De Loose, Ingrid De Meester, Frank Rösch, Pieter Van Der Veken, et al.
Pages: 1 - 10 - From PERK to RIPK1(2023)
Authors: Camilla Scarpellini, Sophie Valembois, Kenneth Goossens, Mike Vadi, Caroline Lanthier, Greta Klejborowska, Pieter Van Der Veken, Hans De Winter, Mathieu J.M. Bertrand, Koen Augustyns
Pages: 1 - 15 - Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics(2023)
Authors: Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken, Frank Roesch
Pages: 1 - 25 - Characterization of structurally diverse ¹⁸F-labeled d-TCO derivatives as a PET probe for bioorthogonal pretargeted imaging(2023)
Authors: Karuna Adhikari, Christel Vangestel, Pieter Van Der Veken, Sigrid Stroobants, Filipe Elvas, Koen Augustyns
Pages: 38252 - 38262 - Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Lisse Decraecker, Valerie Cacheux, Irena Zeiburlina, Michelle De bruyn, Louise Battut, Carlos Moreno Cinos, Davide Ceradini, Eric Espinosa, Gilles Dietrich, et al.
Pages: 1 - 17 - Design, synthesis and evaluation of novel activity-based probes and inhibitors for trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Koen Augustyns, Pieter Van Der Veken
Number of pages: 289 - Highly selective inhibitors of dipeptidyl peptidase 9 (DPP9) derived from the clinically used DPP4-inhibitor vildagliptin(2023)
Authors: Siham Benramdane, Joni De Loose, Nicolò Filippi, Margarida Florindo Espadinha, Olivier Beyens, Yentl Van Rymenant, Laura Dirkx, Murat Bozdag, Koen Augustyns, Guy Caljon, et al.
Pages: 12717 - 12738 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Van Der Veken
Pages: 1 - 16
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)